A multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and clinical efficacy of intravenous infusions of BMS-188667 [abatacept] (10 mg/kg) given monthly in combination with subcutaneous injections of etanercept (25 mg) given twice weekly to subjects with rheumatoid arthritis

Trial Profile

A multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and clinical efficacy of intravenous infusions of BMS-188667 [abatacept] (10 mg/kg) given monthly in combination with subcutaneous injections of etanercept (25 mg) given twice weekly to subjects with rheumatoid arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2006

At a glance

  • Drugs Abatacept; Etanercept
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Nov 2006 Status change
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top